Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients

Pharmacotherapy

Volumn 28, Issue 6, 2008, Pages 691-698

  Cheatham, S Christian ^a   Kays, Michael B ^b   Smith, David W ^c   Wack, Matthew F ^d   Sowinski, Kevin M ^b  

^a St Francis Hospital   (United States)

^b PURDUE UNIVERSITY   (United States)

^c METHODIST HOSPITAL   (United States)

^d Infectious Diseases of Indiana   (United States)

Author keywords

Bacterial infection; Meropenem; Monte Carlo simulation; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CREATININE; MEROPENEM;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL INFECTION; CITROBACTER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DOSAGE SCHEDULE COMPARISON; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; ENTEROBACTER; ESCHERICHIA COLI; FEMALE; HOSPITAL PATIENT; HUMAN; KLEBSIELLA PNEUMONIAE; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; OPEN STUDY; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; THIENAMYCINS;

EID: 47149101068     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.6.691     Document Type: Article

References (35)

1. AstraZeneca Pharmaceuticals. Merrem (meropenem) package insert. Wilmington, DE; 2007.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare associated pneumonia. Am J Respir Crit Care Med 2005;171: 388-416.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
4. Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics- pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 2007;44:79-86.
5. Drusano GL. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin Infect Dis 2003;36(suppl 1):S42-50.
6. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther 2004;26:1187-98.
7. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharmacol 2003;43:1116-23.
8. Lodise TP, Lomaestro BM, Drusano GL. Application of antimicrobial pharmacodynamic concepts into clinical practice: focus on β-lactam antibiotics. Pharmacotherapy 2006;26: 1320-32.
9. Kays MB, Burgess DS, Denys GA. Pharmacodynamic evaluation of six β-lactams against recent isolates of Pseudomonas aeruginosa using Monte Carlo analysis [abstract]. In: Program and abstracts of the 42nd interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2002:642.
10. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2003;60:565-8.
11. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of meropenem and imipenem against Enterbacteriaceae, Acinetobacter baumanii, and Pseudomonas aeruginosa. Pharmacotherapy 2004;24:8-15.
12. Bedikian A, Okamoto MP, Nakahiro RK, et al. Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother 1994;38:151-4.
13. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43:523-7.
14. de Stoppelaar F, Stolk L, van Tiel F, Beysens A, van der Geest S, de Leeuw P. Meropenem pharmacokinetics and pharmacodynamics in patients with ventilator-associated pneumonia. J Antimicrob Chemother 2000;46:150-1.
15. Kitzes-Cohen R, Farin D, Piva G, De Myttenaere-Bursztein SA. Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. Int J Antimicrob Agents 2002;19: 105-10.
16. Ariano RE, Nyhlen A, Donnelly JP, Sitar DS, Harding GKM, Zelenitsky SA. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother 2005;39:32-8.
17. Jaruratanasirikul S, Sriwiriyajan S, Punyo J. Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother 2005;49:1337-9.
18. Novelli A, Adembri C, Livi P, Fallani S, Mazzei T, De Gaudio AR. Pharmacokinetic evaluation of meropenem and imipenem in critically ill patients with sepsis. Clin Pharmacokinet 2005;44:539-49.
19. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol 2006;46:1171-8.
20. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
21. Elkhaili H, Niedergang S, Pompei D, Linger L, Leveque D, Jehl F. High-performance liquid chromatographic assay for meropenem in serum. J Chromatogr B 1996;686:19-26.
22. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother 1992;36:552-7.
23. Benet LZ, Galeazzi RL. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 1979;68:1071-2.
24. Turner PJ. Use of a program-specific website to disseminate surveillance data obtained from the meropenem yearly susceptibility test information collection (MYSTIC) study. Diagn Microbiol Infect Dis 2005;53:273-9.
25. Rhomberg PR, Fritsche TR, Sader HS, Jones RN. Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J Chemother 2005;17:459-69.
26. Rhomberg PR, Jones RN. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn Microbiol Infect Dis 2007;57:207-15.
27. Turnidge JD. The pharmacodynamics of β-lactams. Clin Infect Dis 1998;27:10-22.
28. Zhanel GG, Wiebe R, Dilay L, et al. Comparative review of the carbapenems. Drugs 2007;67:1027-52.
29. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51:1725-30.
30. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumanii, Escherichia coli, and Klebsiella species collected from the United States intensive care units in 2004. Pharmacotherapy 2007;27: 333-42.
31. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 15th informational supplement, M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute, 2005.
32. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP. Comparison of pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 2005;25:935-41.
33. Krueger WA, Bulitta J, Kinzig-Schippers M, et al. Evaluation by Monte Carlo simulation of the pharmacokinetics of two doses of meropenem administered intermittently or as a continuous infusion in healthy volunteers. Antimicrob Agents Chemother 2005;49:1881-9.
34. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic benefits of a meropenem dosage strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2004;61:1264-70.
35. Patel GW, Duquaine SM, McKinnon PS. Clinical outcomes and cost minimization with an alternative dosing regimen for meropenem in a community hospital. Pharmacotherapy 2007;27:1637-43.